文献速递临床试验与 GCP流行病学与生物统计

静脉溶栓后低强度监测与标准监测在急性缺血性卒中患者中的安全性和有效性(OPTIMISTmain):一项国际、实用性、阶梯楔形、整群随机、对照非劣效性试验

Safety and efficacy of low-intensity versus standard monitoring following intravenous thrombolytic treatment in patients with acute ischaemic stroke (OPTIMISTmain): an international, pragmatic, stepped-wedge, cluster-randomised, controlled non-inferiority trial.
PubMed 文献 · Lancet · 2025-05-21

OPTIMISTmain是一项在8个国家114家医院开展的国际实用性阶梯楔形整群随机对照非劣效性试验,纳入4922例NHISS评分<10且临床稳定的急性缺血性卒中静脉溶栓患者,比较低强度监测与标准监测。低强度组31.7%与标准组30.9%在90天mRS评分为2-6分(RR 1.03,95%CI 0.92-1.15,非劣效性p=0.057),症状性颅内出血低强度组0.2% vs 标准组0.4%。作者认为提供了低强度监测非劣效于标准监测的弱证据。

要点

  • 低强度监测组90天mRS 2-6分比例为31.7%,标准监测组为30.9%(RR 1.03,95%CI 0.92-1.15)。
  • 非劣效性检验p=0.057,作者称提供低强度监测非劣效的弱证据。
  • 症状性颅内出血低强度组0.2% vs 标准组0.4%,严重不良事件两组相似(11.1% vs 11.3%)。

核心结论

  • OPTIMISTmain提供弱证据表明,对于神经功能缺损轻至中度且接受溶栓治疗的急性缺血性卒中患者,低强度监测非劣效于标准监测。
  • 作者认为医院可根据当地情况考虑将低强度监测方案纳入卒中服务。

研究设计与样本

  • 国际、实用性、多中心、阶梯楔形、整群随机、对照、非劣效性、盲法终点试验,在8个国家的医院(集群)开展。
  • 纳入连续成人急性缺血性卒中患者,临床稳定、神经功能缺损轻至中度(NIHSS评分<10分),且在按当地指南启动静脉溶栓后2小时内。
  • 参与医院按国家和预计参与者数量分层,随机分配至4个周期内3种实施顺序,以阶梯方式从标准监测(对照)切换为低强度监测(干预)。
  • 低强度监测方案:神经和生命体征评估为每15分钟1次持续2小时,随后每2小时1次持续8小时(标准监测为每30分钟1次持续6小时),之后每4小时1次(标准监测为每1小时1次)直至溶栓后24小时。
  • 主要结局为90天改良Rankin量表评分2分(部分残疾)至6分(死亡)即不良功能结局的参与者比例,由对分组分配设盲的研究人员测量;非劣效性界值为风险比(RR)1.15,在意向治疗人群中分析。

主要发现

  • 181家医院接受资格评估,120家医院同意加入并于2021年4月28日至2024年9月30日间随机分配;其中1家退出、1家未启动、4家未纳入任何患者。
  • 最终114家医院共纳入4922例参与者,低强度监测组2789例,标准监测组2133例。
  • 低强度监测组2552例中809例(31.7%)与标准监测组1963例中606例(30.9%)在90天时改良Rankin量表评分为2-6分(RR 1.03,95%CI 0.92-1.15,非劣效性p=0.057)。
  • 症状性颅内出血在低强度监测组2783例中发生5例(0.2%),标准监测组2122例中发生8例(0.4%)。
  • 严重不良事件例数在低强度监测组(2789例中309例,11.1%)与标准监测组(2133例中240例,11.3%)相似。

关键数值与推荐

  • 纳入标准:临床稳定、NIHSS评分<10分、按当地指南启动静脉溶栓后2小时内的连续成人急性缺血性卒中患者。
  • 主要结局非劣效性界值:风险比(RR)1.15,在意向治疗人群中分析。
  • 低强度监测方案:每15分钟1次持续2小时,每2小时1次持续8小时(标准监测为每30分钟1次持续6小时),每4小时1次(标准监测为每1小时1次)直至溶栓后24小时。

临床怎么用

  • 作者认为医院可根据当地情况考虑将低强度监测方案纳入卒中服务。

局限性

  • 作者称OPTIMISTmain提供的是低强度监测非劣效于标准监测的弱证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The universally accepted best practice protocol for monitoring patients who receive intravenous thrombolysis for acute ischaemic stroke was established in the 1990s. However, the protocol is burdensome for nurses, disrupts the sleep of patients, and is potentially less relevant in patients at low risk of symptomatic intracerebral haemorrhage. We aimed to assess whether implementing a low-intensity monitoring protocol would be as safe and effective as standard high-intensity monitoring for patients with acute ischaemic stroke at low risk. METHODS: OPTIMISTmain was an international, pragmatic, multicentre, stepped-wedge, cluster-randomised, controlled, non-inferiority, blinded-endpoint trial conducted at hospitals (clusters) in eight countries. It was designed to test the non-inferiority of a low-intensity monitoring protocol to a standard protocol among consecutive adults with acute ischaemic stroke who were clinically stable with mild to moderate neurological impairment (score <10 on the National Institutes of Health Stroke Scale) within 2 h of initiation of intravenous thrombolysis according to local guidelines. Participating hospitals were randomly allocated to three sequences of implementation across four periods, stratified by country and projected numbers of participants, in which sites switched from standard monitoring (control) to low-intensity monitoring (intervention) in a stepped manner. The low-intensity monitoring protocol included assessments of neurological and vital signs every 15 min for 2 h, every 2 h for 8 h (vs every 30 min for 6 h for standard monitoring), and every 4 h (vs every 1 h for standard monitoring) until 24 h after thrombolysis. The primary outcome was the proportion of participants with an unfavourable functional outcome defined by a score from 2 (indicating some disability) to 6 (death) on the modified Rankin Scale at 90 days, measured by research staff masked to group allocation. The non-inferiority margin was set at 1·15 for the risk ratio (RR) in the intention-to-treat population. A generalised linear mixed model was used for analysis with adjustments for cluster (hospital site) and time (6-month periods from April, 2021), and imputation of missing outcome data. This trial is registered at Clinicaltrials.gov (NCT03734640) and the Australian New Zealand Clinical Trial Registry (ACTRN 12619001556134p) and is completed. FINDINGS: Of 181 hospitals assessed for eligibility, 120 hospitals agreed to join the trial and were randomly allocated between April 28, 2021, and Sept 30, 2024; however, one hospital withdrew, one was not activated, and four did not enrol any patients. Overall, 4922 participants were enrolled at 114 hospitals, with 2789 participants assigned to the low-intensity monitoring group and 2133 to the standard monitoring group. 809 (31·7%) of 2552 participants in the low-intensity group and 606 (30·9%) of 1963 in the standard monitoring group had a modified Rankin Scale score of 2-6 at 90 days (RR 1·03 [95% CI 0·92-1·15], pnon-inferiority=0·057). Symptomatic intracerebral haemorrhage occurred in five (0·2%) of 2783 patients in the low-intensity group and eight (0·4%) of 2122 patients in the standard monitoring group. The numbers of participants with a serious adverse event were similar between the low-intensity monitoring group (309 [11·1%] of 2789) and the standard monitoring group (240 [11·3%] of 2133). INTERPRETATION: OPTIMISTmain provides weak evidence that low-intensity monitoring is non-inferior to standard monitoring in patients with a mild or moderate level of neurological impairment who receive thrombolysis treatment for acute ischaemic stroke. Hospitals could consider incorporating this approach into stroke services according to local circumstances. FUNDING: National Health and Medical Research Council of Australia; New South Wales Health Investigator Development Grant; University of New South Wales Medicine Non Communicable Diseases Theme Early-Mid Career Research Seed Grant Scheme; Medical Research Future Fund (for conduct in Australia); and Genentech (for conduct in the USA).

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Anderson CS, Summers D, Ouyang M, et al. Safety and efficacy of low-intensity versus standard monitoring following intravenous thrombolytic treatment in patients with acute ischaemic stroke (OPTIMISTmain): an international, pragmatic, stepped-wedge, cluster-randomised, controlled non-inferiority trial. Lancet. 2025. PMID: 40412428. doi:10.1016/S0140-6736(25)00549-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。